Compass Pathways PLC
5Y6
Company Profile
Business description
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Contact
33 Broadwick Street
LondonW1F 0DQ
GBRSector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
156
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,983.30 | 42.10 | -0.47% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,862.61 | 52.59 | -0.20% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,523.69 | 383.46 | 0.65% |
| NZX 50 Index | 12,870.33 | 14.60 | -0.11% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,762.80 | 35.80 | -0.41% |
| SSE Composite Index | 4,069.37 | 23.88 | -0.58% |